EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Buprenorphine Versus Diclofenac for Pain Relief in Acute Pancreatitis: A Double-Blinded Randomized Controlled Trial

Mayank Saini, Jayanta Samanta, Antriksh Kumar, Arup Choudhury, Jahnvi Dhar, Anudeep Jafra, Rajeev Chauhan, Gaurav Muktesh, Pankaj Gupta, Vikas Gupta, Thakur Deen Yadav, Rakesh Kochhar und 3 weitere

Clinical Gastroenterology and Hepatology · 2024-03 · 22 (3) · 532-541.e8

DOI: 10.1016/j.cgh.2023.10.021 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024-03. Verfasst von Mayank Saini und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Buprenorphine, Pancreatitis. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although both nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids are used for analgesia in acute pancreatitis (AP), the analgesic of choice is not known. We compared buprenorphine, an opioid, and diclofenac, an NSAID, for analgesia in AP. METHODS: In a double-blind randomized controlled trial, AP patients were randomized to receive intravenous diclofenac or intravenous buprenorphine. Fentanyl was used as rescue analgesia, delivered through a patient-controlled analgesia pump. Primary outcome was the difference in the dose of rescue fentanyl required. Secondary outcomes were the number of effective and ineffective demands of rescue fentanyl, pain-free interval, reduction in visual analogue scale (VAS) score, adverse events, and organ failure development. RESULTS: Twenty-four patients were randomized to diclofenac and 24 to buprenorphine. The 2 groups were matched at baseline. The total amount of rescue fentanyl required was significantly lower in the buprenorphine group:130 μg, interquartile range (IQR), 80-255 vs 520 μg, IQR, 380-1065 (P < .001). The number of total demands was 32 (IQR, 21-69) in the diclofenac arm vs 8 (IQR, 4-15) in the buprenorphine arm (P < .001). The buprenorphine group had more prolonged pain-free interval (20 vs 4 hours; P < .001), with greater reduction in the VAS score at 24, 48, and 72 hours compared with the diclofenac group. These findings were confirmed in the subgroup of moderately severe/severe pancreatitis. Adverse events profile was similar in the 2 groups. CONCLUSIONS: Compared with diclofenac, buprenorphine appears to be more effective and equally safe for pain management in AP patients, even in the subcohort of moderately severe or severe pancreatitis (Trial Registration number: CTRI/2020/07/026914).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphinePancreatitisHumansDiclofenacPain ManagementAcute DiseaseAnti-Inflammatory Agents, Non-SteroidalAnalgesics, OpioidPainFentanylDouble-Blind Method

Stichwörter der Autor:innen

AnalgesicsNonsteroidal Anti-inflammatory DrugsOpioidsPatient-Controlled AnalgesiaVisual Analogue Scale

Substanzen

DiclofenacBuprenorphineAnti-Inflammatory Agents, Non-SteroidalAnalgesics, OpioidFentanyl

Autor:innen und Institutionen

  • Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address: dj_samanta@yahoo.co.in.
  • Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Anesthesiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Radiodiagnosis, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of GI Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Zitieren

APA

Saini, M., Samanta, J., Kumar, A., Choudhury, A., Dhar, J., Jafra, A., Chauhan, R., Muktesh, G., Gupta, P., Gupta, V., Yadav, T. D., Kochhar, R., Capurso, G., De-Madaria, E., & Facciorusso, A. (2024). Buprenorphine Versus Diclofenac for Pain Relief in Acute Pancreatitis: A Double-Blinded Randomized Controlled Trial. Clinical Gastroenterology and Hepatology, 22(3), 532-541.e8. https://doi.org/10.1016/j.cgh.2023.10.021

Vancouver

Saini M, Samanta J, Kumar A, Choudhury A, Dhar J, Jafra A, et al. Buprenorphine Versus Diclofenac for Pain Relief in Acute Pancreatitis: A Double-Blinded Randomized Controlled Trial. Clinical Gastroenterology and Hepatology. 2024;22(3):532-541.e8. doi:10.1016/j.cgh.2023.10.021

BibTeX
@article{Saini2024,
  author = {Saini, Mayank and Samanta, Jayanta and Kumar, Antriksh and Choudhury, Arup and Dhar, Jahnvi and Jafra, Anudeep and Chauhan, Rajeev and Muktesh, Gaurav and Gupta, Pankaj and Gupta, Vikas and Yadav, Thakur Deen and Kochhar, Rakesh and Capurso, Gabriele and De-Madaria, Enrique and Facciorusso, Antonio},
  title = {Buprenorphine Versus Diclofenac for Pain Relief in Acute Pancreatitis: A Double-Blinded Randomized Controlled Trial},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2024},
  volume = {22},
  number = {3},
  pages = {532--541.e8},
  doi = {10.1016/j.cgh.2023.10.021}
}
Kostenlos starten →